Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC004 in locally advanced/metastatic solid tumors
NCT06658353Phase 3Recruiting
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eratrectinib in solid tumor, sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
eratrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06658353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658353.